Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Cullinan Management ( (CGEM) ) has issued an update.
On January 28, 2025, Cullinan Therapeutics, in collaboration with Taiho Pharmaceutical and Taiho Oncology, announced that their REZILIENT1 trial successfully met its primary endpoint of overall response rate. The trial involved zipalertinib monotherapy for patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. The results, consistent with previous data presentations, are from the Phase 2b part of the study, with plans to present full results at an upcoming international medical conference. The companies intend to seek U.S. regulatory approval in the latter half of 2025.
More about Cullinan Management
Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on creating new standards of care for patients by developing a diversified portfolio of clinical-stage assets targeting key disease drivers or utilizing the immune system to eliminate diseased cells in autoimmune diseases and cancer. The company aims to deliver transformative therapeutics across a wide array of autoimmune and cancer indications, leveraging its expertise in oncology, immunology, and translational medicine.
YTD Price Performance: -15.66%
Average Trading Volume: 545,863
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $608.5M
See more data about CGEM stock on TipRanks’ Stock Analysis page.
